Storia in 9 fonti

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

scmp.comStai leggendo1 g fa

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

originale

thenextweb.com23 h fa

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's plenary in 61 years, targeting a $20B market.

Leggi questa versione → originale

statnews.com1 g fa

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso and Summit Therapeutics' ivonescimab reduced the risk of death by 34% in squamous non-small cell lung cancer patients versus standard treatment, in a Phase III trial published in The Lancet. For biotech and pharma-adjacent tech buyers, the result validates dual-mechanism oncology biologics and strengthens Summit's pipeline valuation ahead of potential ex-China regulatory filings.

Leggi questa versione → originale

fiercepharma.com1 g fa

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival…

Leggi questa versione → originale

biopharmadive.com2 g fa

Akeso, Summit drug extends survival in closely watched lung cancer trial

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."

Leggi questa versione → originale

cnbc.com1 g fa

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Akeso and Summit Therapeutics' bispecific antibody ivonescimab (PD-1/VEGF) reduced mortality risk by 34% in a Phase 3 China trial, extending median overall survival to 27.9 months vs. 23.7 months for standard PD-1 plus chemotherapy in squamous NSCLC. The data reignite the debate over whether PD-1/VEGF combos can succeed Keytruda ($30B+ in annual sales) as the standard-of-care backbone, though generalizability outside China remains unconfirmed until Harmoni-3 global results land in H2 2026.

Leggi questa versione → originale

Akeso lung cancer drug trial raises hopes in US$20b market

Confronto fonti

Akeso lung cancer drug trial raises hopes in US$20b market

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

Akeso, Summit drug extends survival in closely watched lung cancer trial

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Timeline cronologica

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

New drug a ‘promising step forward’ for hard-to-treat lung cancer

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…

Akeso lung cancer drug trial raises hopes in US$20b market

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso lung cancer drug trial raises hopes in US$20b market

Confronto fonti

Akeso lung cancer drug trial raises hopes in US$20b market

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

Akeso, Summit drug extends survival in closely watched lung cancer trial

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Timeline cronologica

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

New drug a ‘promising step forward’ for hard-to-treat lung cancer

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…

Akeso lung cancer drug trial raises hopes in US$20b market

Akeso lung cancer drug cuts death risk 34% in landmark trial